Agenda: Deep Dive into Endocrine-Resistant Breast Cancer
8:00 am Welcome to the Guardant Health Engager
8:05 am Presentation: Clinical Utility of ctDNA in Advanced Breast Cancer Disease
Synopsis
• Metastatic setting: Understand the importance of detecting biomarkers for clinical decisions
• Explore how ctDNA can be used to evaluate molecular response
• Assess why biomarkers are needed to identify mechanisms of resistance
8:25 am Presentation: The Value of ctDNA in Earlier Stages of Breast Cancer & Screening
Synopsis
• Hear about novel therapeutic strategies, modalities and competitive landscape
• Learn about innovation in screening and its impact for earlier intervention in breast cancer
• ctDNA clearance as an endpoint: Understand enrichment and early stop in breast cancer trials
8:45 am Presentation: Targeted Therapies Aimed at Specific Resistance Biomarkers in Breast Cancer
Synopsis
• Hear how ctDNA serial monitoring can be used as a tool to track genomic changes in tumor breast cancer patients
• Understand how changes in ctDNA can correlate to phase II clinical outcomes
• Analyze how ctDNA can be used to identify resistant mechanisms and aid in therapy-selection
9:05 am Panel Discussion & Q&A
9:30 am End of the Guardant Health Engager
Synopsis
If you have any follow up questions after the event, please let us know by emailing info@hansonwade.com